Stocktoria
Aptevo Therapeutics Inc. APVO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-07-20
Aptevo Therapeutics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $3.1M | $12.3M |
| R&D expense | $14.5M | $14.4M | $17.1M | $17.9M | $19.0M |
| Operating income | -$26.3M | -$24.6M | -$28.9M | -$28.6M | -$21.4M |
| Income tax | $0 | — | — | — | — |
| Net income | -$26.0M | -$24.1M | -$17.4M | $8.0M | -$28.5M |
| EPS (diluted) | $-87.27 | $-31460.23 | $-2316.83 | $1.57 | $-6.07 |
| Operating cash flow | -$25.6M | -$23.8M | -$11.7M | -$21.0M | -$21.7M |
| Free cash flow | — | — | — | -$21.1M | -$22.4M |
| Cash & equivalents | $21.6M | $8.7M | $16.9M | $22.6M | $45.0M |
| Total assets | $27.2M | $15.6M | $24.8M | $34.2M | $56.6M |
| Total liabilities | $9.8M | $10.8M | $12.6M | $16.2M | $55.4M |
| Shareholders' equity | $17.4M | $4.8M | $12.2M | $18.0M | $1.2M |
Source: SEC EDGAR filings · CIK 0001671584 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.